Dare Bioscience Stock
Dare Bioscience, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Sabrina Martucci Johnson
- Employees
- 23
- Market cap
- $11 M
- IPO
- 10/04/2014
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a…
Dare Bioscience stock: price history
1D
-2.1%
1W
-6.3%
1M
-0.1%
6M
-75.4%
YTD
-62.5%
1Y
-65.8%
2Y
-79.8%
5Y
-96.2%
10Y
-99.1%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~0% stronger price swings than usual
Ask the agents about Dare Bioscience
Analyst assessment of Dare Bioscience
PRICE TARGET LOW
US$1.00
CONSENSUS
US$1.00
MEDIAN
US$1.00
PRICE TARGET HIGH
US$1.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 02/12/2025
Dare Bioscience stock metrics
P/E
-0.92
P/B
-19.26
EV/EBITDA
-0.58
RETURN ON EQUITY
532.5%
NET MARGIN
-1,590.4%
DEBT/EQUITY
-12.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.9%
FLOAT SHARES
13,620,000
AVG. DAILY VOLUME (30D)
206,936
Insider transactions (SEC)
Steele Robin Joan
RASTETTER WILLIAM H
Matz Gregory W
Kelley Susan L.
Grossman Jessica D.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Dare Bioscience stock
What does Dare Bioscience do?
Dare Bioscience, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Sabrina Martucci Johnson, the company employs around 23 people.
The IPO was on 10/04/2014; the stock trades on NASDAQ under the ticker DARE.
What do analysts say about Dare Bioscience stock?
6 analysts rate the stock, the consensus is Buy (as of 02/12/2025).
The average price target is US$1.00, ranging from US$1.00 to US$1.00, with a median of US$1.00.
This is an external assessment, not a statement by Market Jury.
When does Dare Bioscience report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Dare Bioscience pay a dividend?
No, Dare Bioscience currently does not pay a dividend.
Which stocks are comparable to Dare Bioscience?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Dare Bioscience stock analyzed?
Clicking "Analyze stock" lets five strategies assess Dare Bioscience against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.